Across TCGA pan-cancer cohorts, CELA2B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CELA2B data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CELA2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CELA2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, UCEC, and STAD are the cancer types where CELA2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.439	.019	24	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CELA2B tumor-vs-normal RNA expression · all CELA2B data types